Photo by mykjohnson from unsplash
To determine the effect of TTP399, a hepatoselective glucokinase activator, on the risk of ketoacidosis during insulin withdrawal in individuals with type 1 diabetes (T1D). Click to show full abstract
To determine the effect of TTP399, a hepatoselective glucokinase activator, on the risk of ketoacidosis during insulin withdrawal in individuals with type 1 diabetes (T1D).
Keywords:
insulin withdrawal;
ketoacidosis insulin;
glucokinase activator;
hepatoselective glucokinase;
type diabetes
Journal Title: Diabetes
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!